Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Core Insights - Sonoma Pharmaceuticals, Inc. reported a revenue increase of 22% for the quarter ended December 31, 2025, and 33% for the nine months ended December 31, 2025, compared to the prior year [1] - The company experienced a decrease in net loss and net loss per share for both the three months and nine months ended December 31, 2025, compared to the prior year [1] - EBITDAS loss decreased by $0.4 million and $0.9 million for the three and nine months ended December 31, 2025, respectively, compared to the prior year [1] Company Overview - Sonoma Pharmaceuticals is a global healthcare leader focused on developing and producing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants [1] - The CEO of Sonoma Pharmaceuticals, Amy Trombly, expressed satisfaction with the continued revenue growth, indicating effective execution of the company's strategic priorities [1]